Showing results (341-350 of 464) with videos related to
Sort By:
Pageof 47
Molecular Cancer Therapeutics|April 21, 2017
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent MechanismsMarie D Ralff, Christina L B Kline, Ozan C Küçükkase, et al.Molecular Cancer Research : MCR|December 4, 2020
Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder CancerRahmat K Sikder, Moataz Ellithi, Robert N Uzzo, et al.Nature|September 20, 1997
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1K Somasundaram, H Zhang, Y X Zeng, et al.Cell Cycle (Georgetown, Tex.)|May 10, 2017
Tissue TGF-β expression following conventional radiotherapy and pulsed low-dose-rate radiationJoshua E Meyer, Niklas K Finnberg, Lili Chen, et al.Cell|November 19, 1993
WAF1, a potential mediator of p53 tumor suppressionW S el-Deiry, T Tokino, V E Velculescu, et al.Cancer Research|July 1, 1995
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissuesW S el-Deiry, T Tokino, T Waldman, et al.Communications Biology|May 29, 2020
Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoformYonggang Pei, Nicky Hwang, Fengchao Lang, et al.International Journal of Oncology|April 14, 2000
Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistanceN Ozören, M J Fisher, K Kim, et al.Molecular Cancer Therapeutics|July 18, 2012
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesJoshua E Allen, Roger Ferrini, David T Dicker, et al.Oncotarget|March 13, 2025
Signaling pathway dysregulation in breast cancerDinara Ryspayeva, Attila A Seyhan, William J MacDonald, et al.Pageof 47